| Autor: |
Osamah M. Alfayez, Alanoud A. Alsallum, Adnan F. Aljabri, Faisal S. Almutairi, Ola Al-Azzeh, Ohoud S. Almalki, Majed S. Al Yami, Omar A. Almohammed |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Public Health, Vol 10 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2296-2565 |
| DOI: |
10.3389/fpubh.2022.989072 |
| Popis: |
BackgroundPatients with prediabetes are at higher risk of developing type 2 diabetes. While intensive lifestyle modification is the primary approach to delaying diabetes, metformin has been shown to be effective, especially among patients younger than 60 years and obese (body mass index (BMI) > 35 kg/m2), patients with fasting blood glucose ≥ 6.1 mmol/L or HbA1c ≥ 6%, and women with history of gestational diabetes. Thus, metformin is now recommended as an option for diabetes prevention by the American Diabetes Association (ADA). The use of metformin among patients with prediabetes in Saudi Arabia and their adherence to the guideline's recommendation for the prevention of type 2 diabetes is unknown. This study aimed to identify the prevalence of metformin use among prediabetes patients overall and patients who are more likely to benefit from metformin use per the ADA guidelines.MethodsA retrospective cohort study was conducted encompassing data from three tertiary care hospitals between January 2015 and June 2019. All patients aged 20 to 70 years with prediabetes (HbA1c of 5.7–6.4%) were included, while patients with an established diagnosis of diabetes, creatinine clearance |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
